CytomX Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Basic Share
CytomX Therapeutics, Inc. (CTMX) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.09 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2026-08-06
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-06-30 was -$0.09.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-03-31 was -$0.10, a 137.04% decline year-over-year.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-09-30 was -$0.09, a 228.57% decline year-over-year.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-06-30 was $0.00.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2025 was -$0.15, a 139.47% decline from fiscal 2024.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2024 was $0.38.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2023 was -$0.01.
- CytomX Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2022 was -$1.51.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.09 10-Q · filed 2026-08-06 | -$0.20 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | -$0.10 10-Q · filed 2026-05-07 | ||||||
| 2025-12-31 | -$0.15 10-K · filed 2026-03-16 | ||||||
| 2025-09-30 | -$0.09 10-Q · filed 2025-11-06 | $0.07 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.22 10-Q · filed 2026-08-06 | |||||
| 2025-03-31 | $0.27 10-Q · filed 2026-05-07 | ||||||
| 2024-12-31 | $0.38 10-K · filed 2026-03-16 | ||||||
| 2024-09-30 | $0.07 10-Q · filed 2025-11-06 | $0.15 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | -$0.08 10-Q · filed 2025-08-07 | $0.09 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | $0.17 10-Q · filed 2025-05-12 | ||||||
| 2023-12-31 | -$0.01 10-K · filed 2025-03-06 | ||||||
| 2023-09-30 | $0.04 10-Q · filed 2024-11-07 | -$0.02 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$0.02 10-Q · filed 2024-08-08 | -$0.07 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | -$0.05 10-Q · filed 2024-05-08 | ||||||
| 2022-12-31 | -$1.51 10-K · filed 2024-03-11 | ||||||
| 2022-09-30 | -$0.44 10-Q · filed 2023-11-07 | -$0.35 10-Q · filed 2022-11-08 | -$1.38 10-Q · filed 2023-11-07 | -$1.09 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | -$0.45 10-Q · filed 2023-08-08 | -$0.37 10-Q · filed 2022-08-04 | -$0.94 10-Q · filed 2023-08-08 | -$0.73 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | -$0.49 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | -$0.53 10-K/A · filed 2023-03-27 | -$1.81 10-K/A · filed 2023-03-27 | |||||
| 2021-09-30 | -$0.48 10-K/A · filed 2023-03-27 | -$0.35 10-Q · filed 2022-11-08 | -$1.27 10-K/A · filed 2023-03-27 | -$0.90 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$0.41 10-K/A · filed 2023-03-27 | -$0.30 10-Q · filed 2022-08-04 | -$0.79 10-K/A · filed 2023-03-27 | -$0.55 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$0.38 10-K/A · filed 2023-03-27 | -$0.26 10-Q · filed 2021-05-06 | |||||
| 2020-12-31 | -$0.51 10-K/A · filed 2023-03-27 | -$1.40 10-K/A · filed 2023-03-27 | |||||
| 2020-09-30 | -$0.54 10-K/A · filed 2023-03-27 | -$0.89 10-K/A · filed 2023-03-27 | |||||
| 2020-06-30 | -$0.55 10-K/A · filed 2023-03-27 | -$0.34 10-K/A · filed 2023-03-27 | |||||
| 2020-03-31 | $0.21 10-K/A · filed 2023-03-27 | $0.27 10-Q · filed 2020-05-07 | |||||
| 2019-12-31 | -$2.93 10-K/A · filed 2023-03-27 | ||||||
| 2019-03-31 | -$0.31 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |